Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
insurer, Medicare, does not cover weight-loss drugs, making it tougher for older people to get access to promising new medications
Who Profits Who Profits: Novo Nordisk (NVO) FY2024 Revenue: $61.0B | GLP-1 Revenue (Ozempic + Wegovy): $26.0B | Net Profit: $14.6B | CEO (Lars Fruergaard Jorgensen): $11.8M This issue's mechanism: Novo Nordisk's profit is fundamentally tied to GLP-1 pricing
DHT lin quan n rng tc nh th no
Combines appetite suppression with increased metabolic rate from glucagon agonism
The tiers are based on cumulative sales per quarter and not based on a per order basis
US$ 23.94
US$ 22.97
00157-3/asset/c84fcc65-a3a1-494b-a6da-4db36d90d167/main.assets/gr1_lrg.jpg)
US$ 21.28
US$ 27.27
